Chronic myeloid leukemia
Asciminib and the STAMP inhibitors, treatment-free remission and resistance after ponatinib.
Each dot is one target. Higher means stronger genetic evidence in people (inherited variants or tumour mutations, whichever is stronger). Further right means more evidence from drugs already in trials or approved.
Scores run from 0 to 1 and are Open Targets' summary of how much evidence exists, not the chance a drug will work. The dividing lines sit at 0.5. Hover a dot for its numbers, click it for the target's page. Source: Open Targets Platform, fetched live.
The 15 targets in the top-left of the chart, strongest genetic evidence first. Click one for its drugs, tractability and other cancers.
All 50 targets, by type of evidence
Ranked by overall score for chronic myeloid leukemia on the Open Targets Platform. Darker cells mean stronger evidence of that type.
Peds RMTLmarks the 7 of these targets on the FDA's Pediatric Relevant Molecular Target List: a drug against one of them can be required to be studied in children under the RACE for Children Act.
| Target | Overall | Germline genetics | Somatic | Clinical | genetic literature | Pathways | Literature | Animal models | RNA expr. |
|---|---|---|---|---|---|---|---|---|---|
| ABL1Peds RMTL ABL proto-oncogene 1, non-receptor tyrosine kinase | 0.84 | 0.86 | 0.72 | ||||||
| BCR BCR activator of RhoGEF and GTPase | 0.83 | 0.28 | 0.76 | ||||||
| KITPeds RMTL KIT proto-oncogene, receptor tyrosine kinase | 0.71 | – | 0.53 | ||||||
| SETBP1 SET binding protein 1 | 0.68 | 0.87 | 0.72 | ||||||
| PDGFRBPeds RMTL platelet derived growth factor receptor beta | 0.65 | – | 0.30 | ||||||
| TET2Peds RMTL tet methylcytosine dioxygenase 2 | 0.64 | 0.71 | 0.72 | ||||||
| FYN FYN proto-oncogene, Src family tyrosine kinase | 0.60 | – | – | ||||||
| LYN LYN proto-oncogene, Src family tyrosine kinase | 0.60 | – | – | ||||||
| BLK BLK proto-oncogene, Src family tyrosine kinase | 0.60 | – | – | ||||||
| SRC SRC proto-oncogene, non-receptor tyrosine kinase | 0.59 | – | – | ||||||
| HCK HCK proto-oncogene, Src family tyrosine kinase | 0.59 | – | – | ||||||
| FGR FGR proto-oncogene, Src family tyrosine kinase | 0.58 | – | – | ||||||
| YES1 YES proto-oncogene 1, Src family tyrosine kinase | 0.58 | – | – | ||||||
| EPHA2Peds RMTL EPH receptor A2 | 0.58 | – | – | ||||||
| LCK LCK proto-oncogene, Src family tyrosine kinase | 0.58 | – | – | ||||||
| SRMS src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation sites | 0.58 | – | – | ||||||
| FRK fyn related Src family tyrosine kinase | 0.58 | – | – | ||||||
| GRB2 growth factor receptor bound protein 2 | 0.55 | – | – | ||||||
| GAB2 GRB2 associated binding protein 2 | 0.54 | – | – | ||||||
| IFNAR2 interferon alpha and beta receptor subunit 2 | 0.53 | – | – | ||||||
| IFNAR1 interferon alpha and beta receptor subunit 1 | 0.52 | – | – | ||||||
| RRM2 ribonucleotide reductase regulatory subunit M2 | 0.51 | – | – | ||||||
| RRM1 ribonucleotide reductase catalytic subunit M1 | 0.51 | – | – | ||||||
| RRM2B ribonucleotide reductase regulatory TP53 inducible subunit M2B | 0.51 | – | – | ||||||
| CSF3R colony stimulating factor 3 receptor | 0.49 | – | 0.61 | ||||||
| ASXL1 ASXL transcriptional regulator 1 | 0.49 | 0.21 | 0.72 | ||||||
| JAK2Peds RMTL Janus kinase 2 | 0.48 | – | 0.57 | ||||||
| GATA2 GATA binding protein 2 | 0.48 | – | 0.76 | ||||||
| RUNX1 RUNX family transcription factor 1 | 0.47 | – | 0.72 | ||||||
| PIK3R1 phosphoinositide-3-kinase regulatory subunit 1 | 0.47 | – | – | ||||||
| ETV6 ETS variant transcription factor 6 | 0.47 | – | 0.76 | ||||||
| DDX41 DEAD-box helicase 41 | 0.46 | – | – | ||||||
| SRSF2 serine and arginine rich splicing factor 2 | 0.46 | 0.60 | 0.61 | ||||||
| AMER1 APC membrane recruitment protein 1 | 0.46 | – | 0.57 | ||||||
| APC APC regulator of Wnt signaling pathway | 0.44 | – | 0.46 | ||||||
| CUX1 cut like homeobox 1 | 0.44 | – | 0.46 | ||||||
| SF3B1 splicing factor 3b subunit 1 | 0.44 | – | 0.57 | ||||||
| CBL Cbl proto-oncogene | 0.43 | – | 0.68 | ||||||
| PIK3CAPeds RMTL phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | 0.42 | – | 0.30 | ||||||
| U2AF1 U2 small nuclear RNA auxiliary factor 1 | 0.42 | – | 0.68 | ||||||
| TP63 tumor protein p63 | 0.42 | – | 0.68 | ||||||
| NRAS NRAS proto-oncogene, GTPase | 0.42 | – | 0.54 | ||||||
| TOP2A DNA topoisomerase II alpha | 0.41 | – | – | ||||||
| POLA1 DNA polymerase alpha 1, catalytic subunit | 0.41 | – | – | ||||||
| POLE2 DNA polymerase epsilon 2, accessory subunit | 0.41 | – | – | ||||||
| PRIM1 DNA primase subunit 1 | 0.41 | – | – | ||||||
| KRAS KRas proto-oncogene, GTPase | 0.41 | – | 0.53 | ||||||
| POLD1 DNA polymerase delta 1, catalytic subunit | 0.41 | – | – | ||||||
| POLA2 DNA polymerase alpha 2, accessory subunit | 0.40 | – | – | ||||||
| POLE DNA polymerase epsilon, catalytic subunit | 0.40 | – | – |
26 biomarkers in Chronic myeloid leukemia have validated or clinical evidence in CIViC
Accepted evidence from CIViC, the open (CC0) expert-curated knowledgebase, searched by the disease name “Chronic Myeloid Leukemia”. Level A is validated (for example in guidelines or an approval), level B comes from clinical trials or studies. 322 accepted items exist; the first 100 were read. This is the published evidence, not treatment advice.
- BCR::ABL1 Fusion level A
- BCR::ABL1 Fusion AND ABL1 T315I level B
- ABL1 TKD Mutation level B
- ABL1 Non-P-Loop Mutation level B
- ABL1 P-Loop Mutation level B
- BCR::ABL1 Fusion AND ABL1 F317L level B
- BCR::ABL1 Fusion AND ABL1 G250E level B
- BCR::ABL1 Fusion AND ABL1 Y253H level B
- JAK2 V617F level B
- BCL2L11 Deletion Polymorphism level B
- BCR::ABL1 Fusion AND ( ABL1 F317L OR ABL1 F317V ) level B
- BCR::ABL1 Fusion AND ABL1 E255K level B